SCHEMBL24826178

SCHEMBL24826178

Cc1cn(C2COC2)cn1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.33
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930381 0.85 LRRK2 (0.37)
SCHEMBL18377886 0.81
SCHEMBL14704037 0.78 CDK5 (0.38)
SCHEMBL20325978 0.78 CDK5 (0.39)
SCHEMBL19732426 0.78 HTR2A (0.35)
SCHEMBL18250753 0.76 CDK5 (0.39)
SCHEMBL14926117 0.76 KIT (0.33)
SCHEMBL24496307 0.76 AR (0.32)
SCHEMBL24826177 0.76
SCHEMBL24501900 0.76 CPB2 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO disclosed